YAP/TAZ are mechanoregulators of TGF-β-Smad signaling and renal fibrogenesis

SG Szeto, M Narimatsu, M Lu, X He… - Journal of the …, 2016 - journals.lww.com
SG Szeto, M Narimatsu, M Lu, X He, AM Sidiqi, MF Tolosa, L Chan, K De Freitas, JF Bialik…
Journal of the American Society of Nephrology, 2016journals.lww.com
Like many organs, the kidney stiffens after injury, a process that is increasingly recognized
as an important driver of fibrogenesis. Yes-associated protein (YAP) and transcriptional
coactivator with PDZ-binding motif (TAZ) are related mechanosensory proteins that bind to
Smad transcription factors, the canonical mediators of profibrotic TGF-β responses. Here, we
investigated the role of YAP/TAZ in the matrix stiffness dependence of fibroblast responses
to TGF-β. In contrast to growth on a stiff surface, fibroblast growth on a soft matrix led to …
Abstract
Like many organs, the kidney stiffens after injury, a process that is increasingly recognized as an important driver of fibrogenesis. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are related mechanosensory proteins that bind to Smad transcription factors, the canonical mediators of profibrotic TGF-β responses. Here, we investigated the role of YAP/TAZ in the matrix stiffness dependence of fibroblast responses to TGF-β. In contrast to growth on a stiff surface, fibroblast growth on a soft matrix led to YAP/TAZ sequestration in the cytosol and impaired TGF-β–induced Smad2/3 nuclear accumulation and transcriptional activity. YAP knockdown or treatment with verteporfin, a drug that was recently identified as a potent YAP inhibitor, elicited similar changes. Furthermore, verteporfin reduced YAP/TAZ levels and decreased the total cellular levels of Smad2/3 after TGF-β stimulation. Verteporfin treatment of mice subjected to unilateral ureteral obstruction similarly reduced YAP/TAZ levels and nuclear Smad accumulation in the kidney, and attenuated renal fibrosis. Our data suggest that organ stiffening cooperates with TGF-β to induce fibrosis in a YAP/TAZ-and Smad2/3-dependent manner. Interference with this YAP/TAZ and TGF-β/Smad crosstalk likely underlies the antifibrotic activity of verteporfin. Finally, through repurposing of a clinically used drug, we illustrate the therapeutic potential of a novel mechanointerference strategy that blocks TGF-β signaling and renal fibrogenesis.
Lippincott Williams & Wilkins